REMEGEN CO. LTD YC 1 - Asset Resilience Ratio

Latest as of December 2025: 16.77%

REMEGEN CO. LTD YC 1 (REG) has an Asset Resilience Ratio of 16.77% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read REMEGEN CO. LTD YC 1 (REG) total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

€1.22 Billion

≈ $1.42 Billion USD Cash + Short-term Investments

Total Assets

€7.25 Billion

≈ $8.47 Billion USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2025–2025)

This chart shows how REMEGEN CO. LTD YC 1's Asset Resilience Ratio has changed over time. See REMEGEN CO. LTD YC 1 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Liquid Assets Composition Over Time

This chart breaks down REMEGEN CO. LTD YC 1's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see REG asset base.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€1.22 Billion	16.77%
Total Liquid Assets	€1.22 Billion	16.77%

Asset Resilience Insights

Good Liquidity Position: REMEGEN CO. LTD YC 1 maintains a healthy 16.77% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

REMEGEN CO. LTD YC 1 Industry Peers by Asset Resilience Ratio

Compare REMEGEN CO. LTD YC 1's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	Biotechnology	16.06%
ABCELLERA BIOLOGICS F:8QQ	Biotechnology	32.12%
Gempharmatech Co. Ltd. A SHG:688046	Biotechnology	23.95%
Sinopep-Allsino Biopharmaceutical Co. Ltd. A SHG:688076	Biotechnology	0.91%

Annual Asset Resilience Ratio for REMEGEN CO. LTD YC 1 (2025–2025)

The table below shows the annual Asset Resilience Ratio data for REMEGEN CO. LTD YC 1.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	16.77%	€1.22 Billion ≈ $1.42 Billion	€7.25 Billion ≈ $8.47 Billion	--

pp = percentage points

About REMEGEN CO. LTD YC 1

F:REG Germany Biotechnology

Market Cap

$1.95 Billion

€1.67 Billion EUR

Market Cap Rank

#6207 Global

#938 in Germany

Share Price

€8.01

Change (1 day)

-1.18%

52-Week Range

€7.14 - €12.79

All Time High

€13.60